Activity of Caspofungin and Voriconazole against Clinical Isolates of <i>Candida </i>and Other Medically Important Yeasts by the CLSI M-44A Disk Diffusion Method with Neo-Sensitabs Tablets

Vol. 54, No. 1, 2008

Free Abstract Article (References) Article (PDF 143 KB)

Microbiology

Activity of Caspofungin and Voriconazole against Clinical Isolates of Candida and Other Medically Important Yeasts by the CLSI M-44A Disk Diffusion Method with Neo-Sensitabs Tablets
A.J. Carrillo-Muñoz^a, G. Quindós^d, O. del Valle^b, P. Santos^e, G. Giusiano^f, P.A. Ezkurra^d, M.D. Estivill^c, J.B. Casals^g

^aDepartamento de Microbiología, ACIA,
^bServicio de Microbiología, Hospitals Vall d'Hebrón,
^cALTHAIA Hospitals, Manresa, Barcelona, y
^dDepartamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina, Universidad del País Vasco, Bilbao, Spain;
^eHospital de Pediatría, J.P. Garrahan, Buenos Aires, y
^fDepartamento de Micología, Instituto de Medicina Regional, Universidad Nacional del Nordeste, Resistencia, Argentina;
^gRosco Diagnostica AS, Taastrup, Denmark

Address of Corresponding Author

Chemotherapy 2008;54:38-42 (DOI: 10.1159/000112414)

Key Words

Disk diffusion
Susceptibility
Candida
Neo-Sensitabs
Caspofungin
Voriconazole
Fluconazole
Amphotericin B
Ketoconazole
Itraconazole

Abstract

In vitro activity of caspofungin and vori conazole against 184 clinical isolates of Candida and other medically important yeasts in comparison with that of fluconazole, ketoconazole, itraconazole and amphotericin B was determined by using a disk diffusion method (Neo-Sensitabs) standardized according to the recommendations of the CLSI documents M44-A and M44-S1 (same medium: Mueller-Hinton plus methylene blue; inoculum and minimal inhibitory concentration/zone breakpoints). Seventy-two percent of clinical isolates were susceptible to caspofungin, 23.6% showed an intermediate susceptibility (most of them were Candida parapsilosis) and 4.3% were resistant (values for Candida spp. were 71.2, 23.8 and 5%, respectively). For voriconazole, 96.7% of clinical isolates were susceptible and 3.3% were resistant (Candida spp.: 96 and 3.8%, respectively). Both caspofungin and voriconazole showed high activity against a wide variety of clinically important yeasts.

Author Contacts

Dr. Alfonso-Javier Carrillo-Muñoz
Departamento de Microbiología
ACIA, PO Box 10178
ES-08080 Barcelona (Spain)
Tel./Fax +34 93 429 71 20, E-Mail acarrillo@ya.com

Article Information

Received: July 11, 2006
Accepted after revision: February 25, 2007
Published online: December 10, 2007
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 2, Number of References : 25

Medline Abstract (ID 18073469)

Download Citation

This journal is part of the fourth subject package of the Karger

Journal Archive Collection

Information on packages (PDF)
Free sample issues

For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service.